, Volume 29, Issue 3, pp 236–261 | Cite as

Clinical Application of Inhibitors of Fibrinolysis

  • M. Verstraete
Review Article


The basic proteinase inhibitor from bovine organs, aprotinin, was first identified in 1930 and its effect on enzyme and other biological systems has since been extensively studied. Aprotinin can only be administered intravenously and has a half-life of about 2 hours. Its administration at the start of cardiopulmonary bypass surgery appears to reduce blood loss and to protect against global myocardial ischaemia. Similarly, a smaller infarct size seems to result from early administration of aprotinin within the first hour after myocardial infarction, though further studies are needed to confirm this effect. A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used. Aprotinin is also effective as adjuvant treatment in traumatic haemorrhagic shock. The recommended loading dose is 15,000 to 20,000 KIU/kg bodyweight administered as a short intravenous infusion, followed by 50,000 KIU/hour by continuous infusion. Side effects of aprotinin are very rare.

∈-Aminocaproic acid (EACA), p-aminomethylbenzoic acid (PAMBA) and tranexamic acid are synthetic antifibrinolytic amino acids. Saturation of the lysine binding sites of plasminogen with these inhibitors displaces plasminogen from the fibrin surface. On a molar basis tranexamic acid is at least 7 times more potent that ∈-aminocaproic acid and twice as potent as p-aminomethylbenzoic acid. All 3 compounds are readily absorbed from the gastrointestinal tract and excreted in active form in the urine. The plasma half-life of tranexamic acid is about 80 minutes. The main indications for tranexamic acid are the prevention of excessive bleeding after tonsillectomy, prostatic surgery, and cervical conisation, and primary and IUD-induced menorrhagia. It is possible that gastric and intestinal bleeding can also be reduced as well as recurrent epistaxis. Tranexamic acid could also be useful after ocular trauma. The value of fibrinolysis inhibitors in the prevention of bleeding after tooth extraction in patients with haemophilia is well documented, as is the treatment of hereditary angioneurotic oedema.

The usual dose of tranexamic acid is 0.5 to 1g (10 to 15 mg/kg bodyweight) given intravenously 2 to 3 times daily, or 1 to 1.5g orally 3 to 4 times daily. This dose needs to be reduced in patients with renal insufficiency. The main side effects of tranexamic acid are nausea or diarrhoea.


Aprotinin Plasmin Tranexamic Acid Central Corneal Thickness Trasylol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahlberg, A.; Eriksson, O. and Kjellman, H.: Diffusion of tranexamic acid to the joint. Acta Orthopaedica Scandinavica 47: 486–488 (1976).PubMedGoogle Scholar
  2. Ambrus, J.L.; Schimert, G.; Lajos, T.Z.; Ambrus, CM.; Mink, I.B.; Lassmann, H.B.; Moore, R.H. and Melzer, J.: Effect of antifibrinolytic agents and estrogens on blood loss and blood coagulation factors during open heart surgery. Journal of Medicine, Experimental and Clinical 2: 65–81 (1971).Google Scholar
  3. Ambrus, J.L.; Wilkens, H.; Ambrus, CM. and Back, N.: Effect of the protease inhibitor Trasylol on cholincsterase levels and on susceptibility to succinylcholine Research Communications in Chemical Pathology and Pharmacology 1: 141–147 (1970).Google Scholar
  4. Amris, C.J.; Inhibition of fibrinolytic and thromboplastic activity by Trasylol. Scandinavian Journal of Haematology 3: 19–32 (1966).PubMedGoogle Scholar
  5. Andersson, L.; Erikson, O.; Hedlund, P.O.; Kjellman, H. and Lindqvist, B.: Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urological Research 6: 83–88 (1978).PubMedGoogle Scholar
  6. Andersson, L.; Nilsson, I.M.; Colleen, S.; Grandstrand, B. and Melander, B.: Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Annals of the New York Academy of Sciences 146: 642–658 (1968).PubMedGoogle Scholar
  7. Andersson, L.; Nilsson, I.M.; Nilehn, J.E.; Hedner, U.; Grandstrand, B. and Melander, B.: Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scandinavian Journal of Haematology 2: 230–247 (1965).PubMedGoogle Scholar
  8. Aoki, N. and Yoshida, N.: Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation. Blood 52: 1–12 (1978).PubMedGoogle Scholar
  9. Åstedt, B.; Glifberg, I.; Mattson, W. and Trapé, C.: Arrest of growth of ovarian tumor by tranexamic acid. Journal of the American Medical Association 238: 154–155 (1977).PubMedGoogle Scholar
  10. Åstedt, B. and Nilsson, M.: Recurrent abruptio placentae with the fibrinolytic inhibitor tranexamic acid. British Medical Journal 1: 756–757 (1978).PubMedGoogle Scholar
  11. Balldin, G.; Gustafsson, E.-L and Ohlsson, K.: Influence of plasma protease inhibitors and Trasylol on trypsin-induced brady-kinin-release in vitro and in vivo. European Surgical Research 12: 260–269 (1980).PubMedGoogle Scholar
  12. Balldin, G. and Ohlsson, K.: Demonstration of pancreatic protease-antiprotease complexes in the peritoneal fluid of patients with acute pancreatitis. Surgery 85: 451–456 (1979).PubMedGoogle Scholar
  13. Barer, D.; Ogilvie, A.; Coggon, D.; Henry, D; Atkinson, M. and Langman, M.J.S.: Cimetidine and tranexamic acid in the treatment of acute upper gastrointestinal bleeding (Unpublished data, 1982).Google Scholar
  14. Barer, D.; Ogilvie, A.; Henry, D.; Dronfield, M.; Coggon, D.; French, S.; Ellis, S.; Atkinson, M. and Langman, M.: Cimetidine and tranexamic acid in the treatment of acute uppergastrointestinal tract bleeding. New England Journal of Medicine 308: 1571–1575 (1983).PubMedGoogle Scholar
  15. Bartheis, M.; Oestern, H.J.; Sturm, J.; Trente, O. and Kolbow, H.: Investigations into clotting changes in polytraumatised patients treated with heparin or Trasylol. (Abstract). Presented at the 3rd International Symposium on Proteases — Antiproteases in Ginical Practice, 21–23 October, 1982Google Scholar
  16. Beck, O.J. and Oeckler, R.: Frühdiagnose und Therapie der Aneurysmablutungen. Münchener Medizinische Wochenschrift 123: 561–564 (1981).PubMedGoogle Scholar
  17. Beck. O.J. and Oeckler, R.: Subarachnoid haemorrhage. (Correspondence). British Medical Journal 284: 1050 (1982).Google Scholar
  18. Bennett, A.E.; Ingram, G.I.C. and Inglish, P.J.: Antifibrinolytic treatment in haemophilia: A controlled trial of prophylaxis with tranexamic acid. British Journal of Haematology 24: 83–88 (1973).PubMedGoogle Scholar
  19. Bergmann, S.R.; Fox, K.A.A.; Ter-Pogossian, M.M.; Sobel, B.E. and Collen, D.: Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 220: 1181–1183 (1983).PubMedGoogle Scholar
  20. Bergqvist, D.; Dahlgren, S. and Hessman, Y.: Local inhibition of the fibrinolytic system in patients with massive upper gastrointestinal hemorrhage. Uppsala Journal of Medical Science 85: 173–178 (1980).Google Scholar
  21. Biggs, J.C.; Hugh, T.B. and Dodds, A.J.: Tranexamic acid and upper gastrointestinal haemorrhage. A double blind trial. Gut 17: 729–734 (1976).PubMedGoogle Scholar
  22. Biswas, C.K.; Reid Milligan, D.A.; Agte, S.D.; Kenward, D.H. and Tillex, P.J.B.: Acute renal failure and myopalhy after treatment with aminocaproic acid. British Medical Journal 2: 115–116 (1980).Google Scholar
  23. Blohmé, G.: Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Medica Scandinavica 192: 293–298 (1972).PubMedGoogle Scholar
  24. Blombäck, B.; Blombäck, M. and Olsson, P.: Action of a protcolytic enzyme inhibitor on blood coagulation in vitro. Thrombosis et Diathesis Haemorrhagica 18: 190–197 (1967).PubMedGoogle Scholar
  25. Borst, H.G.; Haverich, A.; Walterbusch, G. and Maatz, W.: Fibrin adhesive: An important hemostatic adjunct in cardiovascular operations. Journal of Thoracic and Cardiovascular Surgery 84: 548–553 (1982).PubMedGoogle Scholar
  26. Bramsen, T.: Traumatic hyphaema treated with the antifibrinolytic drug tranexamic acid. I. Acta Ophthalmologica 54: 250–256 (1976).PubMedGoogle Scholar
  27. Bramsen, T.: Traumatic hyphaema treated with the antifibrinolytic drug tranexamic acid. II. Acta Ophthalmologica 55: 616–620 (1977).PubMedGoogle Scholar
  28. Bramsen, T.: A double-blind study on the influence of central corneal thickness after trabeculectomy for glaucoma simplex. Acta Ophthalmologica 56: 998–1005 (1978).PubMedGoogle Scholar
  29. Bramsen, T.; Corydon, L. and Enters, N.: A double-blind study of the influence of tranexamic acid on the central corneal thickness after cataract extraction. Acta Ophthalmologica 55: 665–673 (1977).PubMedGoogle Scholar
  30. Bramsen, T. and Ehlers, N.: Bullous keratopathy (Fuchs’ endothelial dystrophy) treated systematically with 4-trans-aminocyclohexano-carboxylic acid. Acta Ophthalmologica 55: 665–673 (1977).PubMedGoogle Scholar
  31. Brower, M.S. and Harpel, P.C.: Proteolytic cleavage and inactivation of α2-plasmin inhibitor and C1-inactivator by human polymorphonudear leukocyte elastase. Journal of Biological Chemistry 257: 9849–9854 (1982).PubMedGoogle Scholar
  32. Burns, J.W.; Goodpasture, J.C.; Friel, P.; Wheeler, R. and Zaneveld, L.J.D.: Development and evaluation of an inhibitorreleasing matrix for intrauterine devices. Contraception 26: 521–533 (1982).PubMedGoogle Scholar
  33. Callender, S.T.; Warner, G.T. and Cope, E: Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal 4: 214–216 (1970).PubMedGoogle Scholar
  34. Castelli, G. and Vogt, E.: Der Erfolg einer antifibrinolytischen Behandlung mit Tranexamsaure zur Reduktion der Blutverlustes während und nach Tonsillektomien. Schweizerische Medizinishe Wochenschrift 107: 780–784 (1977).Google Scholar
  35. Cecena-Seldner, F.A. and Villareal, B.S.: Effect of the kallikrein inhibitor aprotinin on myocardial ischemia and necrosis in man. Angiology 31: 488–496 (1980).Google Scholar
  36. Chakrabarti, A. and Collett, K.A.: Purpuric rash due to epsilonaminocaproic acid. British Medical Journal 2: 197–198 (1980).Google Scholar
  37. Chandra, B.: Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: A double blind clinical trial. Annals of Neurology 3: 502–504 (1978).PubMedGoogle Scholar
  38. Chasapakis, G. and Dimas, C.: Possible interaction between muscle relaxants and the kallikrein-trypsin inactivator ‘Trasylol’. Report of three cases. British Journal of Anaesthesia 38: 838–839 (1966).PubMedGoogle Scholar
  39. Collen, D.: On the regulation and control of fibrinolysis. Thrombosis and Haemostasis 2: 77–89 (1980).Google Scholar
  40. Collen, D.; Stassen, J.M. and Verstraete, M.: Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of thrombus and route of administration. Journal of Clinical Investigation 71: 368–376 (1983).PubMedGoogle Scholar
  41. Collen, D.; Topol, E.J.; Tiefenbrunn, A.J.; Gold, H.K.; Weisfeldt, MX.; Sobel, B.E.; Leinbach, R.C.; Brinker, J.A.; Ludbrook, Ph.A.; Yasuda, T.; Bulkley, B.H.; Robison, A.K.; Hutter, A.M.; Bell W.R.; Spadaro, J.J.; An Khaw, B. and Grossbard, E.B.: Coronary thrombolysis with recombinant human tissue-type plasminogen activator. A prospective randomized placebo controlled trial. New England Journal of Medicine (In press, 1984).Google Scholar
  42. Cormack, F.; Chakrabarti, R.R.; Jouhar, A.J. and Fearnley, G.R.: Tranexamic acid in upper gastrointestinal haemorrhage. Lancet 1: 1207–1208 (1973).PubMedGoogle Scholar
  43. Cox, H.T.; Poller, L. and Thomson, J.M.: Gastric fibrinolysis — a possible aetiological link with peptic ulcer. Lancet 1: 1300–1302 (1967).PubMedGoogle Scholar
  44. Cox, H.T.; Poller, L. and Thomson, J.M.: Evidence for the release of gastric fibrinolytic activity into peripheral blood. Gut 10: 404–407 (1969).PubMedGoogle Scholar
  45. Davies, D. and Howell, D.A.: Tranexamic acid and arterial thrombosis. Lancet 1: 49 (1977).PubMedGoogle Scholar
  46. Davies, R.J.; Lane, D.A.; McGregor, I.R. and Preston, F.E.: The neutralisation of heparin by Trasylol. Thrombosis Research 17: 533–537 (1980).PubMedGoogle Scholar
  47. Deklerk, J.; Benzer, H.; Haider, W.; Pauser, G. and Stellwag, F.: Beeinflussung des Kininogen-Kininsystems durch einen Kallikreinhemmer bei Operationen am offenen Herzen in extracorporaler Zirkulation. Anaesthesist 26: 639–643 (1977).PubMedGoogle Scholar
  48. Diaz, P.E.; Fishbein, M.C.; Davis, MA; Askenazi, J. and Maroko, P.R.: Effect of the kallikrein inhibitor aprotinin on myocardial ischemic injury after coronary occlusion in the dog. American Journal of Cardiology 40: 541–549 (1977).PubMedGoogle Scholar
  49. Dietze, G.: Neue Aspekte zur durchblutungssteigernden und insulinähnlichen Wirkung der Muskelarbeit: Mögliche Beteiligund des Kallikrein-Kinin-Prostaglandin Systems. Klinische Wochenschrift 60: 429–444 (1982).PubMedGoogle Scholar
  50. Dietze, G. and Wicklmayr, M.: Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during muscular work. FEBS Letters 74: 205–208 (1977).PubMedGoogle Scholar
  51. Doenicke, A.; Gesing, H.; Krumey, I. and Schmidinger, St.: Influence of aprotinin (Trasylol) on the action of suxamethonium. British Journal of Anaesthesiology 42: 943–960 (1970).Google Scholar
  52. Dubber, A.H.; McNicol, G.P. and Douglas, A.S.: Amino methyl cyclohexane carboxylic acid (AMCHA), A new synthetic fibrinolytic inhibitor. British Journal of Haematology 11: 237–245 (1965).PubMedGoogle Scholar
  53. Dubber, A.H.; McNicol, G.P.; Douglas, A.S. and Melander, B.: Some properties of the antifibrinolytically active isomer of amino-methylcyclohexanocarboxylic acid. Lancet 2: 1317–1319 (1964).PubMedGoogle Scholar
  54. Eigler, F.W. and Stock, W.: Verminderung des postischämischen Extremitätenödems an der Ratte durch einen Proteinasenhemmer. Klinische Wochenschrift 46: 1283–1284 (1968).PubMedGoogle Scholar
  55. Eisenbach, J.; Heine, H. and Bereiter-Hahn, J.: Capillary cinematographic investigations of damage to the terminal vascular bed in the rabbit mesentery after intestinal strangulation; in Breddin et al. (Eds) New Aspects of Trasylol Therapy, Vol. 7, pp. 211–218 (F.K. Schattauer Verlag, Stuttgart/New York 1975).Google Scholar
  56. Ekvärn, S.: Summary and evaluation of toxicological data. Data on file, KabiVitrum AB, Stockholm, Sweden (1983).Google Scholar
  57. Engqvist, A.; Broström, O.; von Feilitzen, F.; Halldin, M.; Nyström, B.; Öst, A.; Reichard, H.; Sandquist, G.; Törngren, S. and Wedlung, J.E.: Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract. A double-blind study. Scandinavian Journal of Gastroenterology 14: 839–844 (1979).PubMedGoogle Scholar
  58. Eriksson, O.; Kjellman, H. and Nilsson, L.: Tranexamic acid in human milk after oral administration of Cyklokapron® to lactating women (Data on file, Kabi AB, Stockholm, 1971a).Google Scholar
  59. Eriksson, O.; Kjellman, H. and Schannong, M.: The biological availability of Cyklokapron tablets compared with Cyklokapron solution administered orally. (Data on file, Kabi AB, Stockholm, 1971b).Google Scholar
  60. Evans, B.E. and Aledort, L.M.: Hemophilia and dental treatment. Journal of the American Dental Association 96: 827–834 (1976).Google Scholar
  61. Flameng, W.; Van de Werf, F.; Vanhaecke, J.; Verstraete, M. and Collen, D.: Coronary thrombolysis and infarct size reduction following intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates. Journal of Clinical Investigation (In press 1984).Google Scholar
  62. Fletcher, A.P.; Alkjaersig, N. and Sherry, S.: Fibrinolytic mechanisms and the development of thrombolytic therapy. American Journal of Medicine 33: 738–752 (1962).PubMedGoogle Scholar
  63. Fodstad, H.; Liliequist, B.; Shannong, M. and Thulin, CA.: Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surgical Neurology 10: 9–15 (1978).PubMedGoogle Scholar
  64. Fodstad, H.; Forsell, A.; Liliequeist, B. and Schannong, M.: Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid haemorrhage: A consecutive controlled trial. Neurosurgery 8: 158–165 (1981).PubMedGoogle Scholar
  65. Forbes, C.D.; Barr, R.D.; Reed, G.; Thomson, C.; Prentice, C.R.M.; McNicol, G.P. and Douglas, A.S.: Thranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. British Medical Journal 2: 311–313 (1972).PubMedGoogle Scholar
  66. Freeman, J.G.; Turner, G.A.; Venables, C.W. and Latner, A.L.: Serial use of aprotinin and incidence of allergic reactions. Current Medical Research and Opinion 8: 559–561 (1983).PubMedGoogle Scholar
  67. Fritz, H.; Oppitz, K.H.; Meckl, D.; Kemkes, B.; Haendle, H.; Schult, H. and Werle, E.: Verteilung und Ausscheidung von natürlich vorkommenden und chemisch modifizierten Proteinaseninhibitoren nach intravenöser Injektion bei Ratte, Hund (und Mensch). Hoppe-Seylers Zeitschrift für Physiologische Chemie 350: 1541–1550 (1969).Google Scholar
  68. Fritz, H. and Wunderer, G.: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittel-Forschung 33: 479–494 (1983).PubMedGoogle Scholar
  69. Fürstenberg, H.S.: Experimentelle Untersuchungen über den Einfluss des Ferment-Inhibitors Trasylol bei der Blutkonservierung. Anaesthesist 14: 109–113 (1965).Google Scholar
  70. Gamba, G.; Fornasari, P.M.; Grignani, G.; Dolci, D. and Colloi, D.: Haemostasis during transverical prostatic adenectomy. Blut 39: 89–98 (1979).PubMedGoogle Scholar
  71. Ganrot, P.O.: Inhibition of the trypsin-α2-macroglobulin complex by the protease inhibitor from bovine lung. Arkiv För Kemi 26: 583–591 (1967).Google Scholar
  72. Gastpar, H.; Kastenbauer, E.R. and Behbehani, A.A.: Erfahrungen mit einem humanen Fibrinkleber bei operativen Eingriffen im Kopf-Hals-Bereich. Laryngologie, Rhinologie, Otologie 58: 389–399 (1979).PubMedGoogle Scholar
  73. Gelmers, J.H.: Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochirurgica 52: 45–50 (1980).PubMedGoogle Scholar
  74. Genicot, R.: Le traitement des saignements dus aux stérilets par un inhibiteur de protéinases. Revue Medicale de Liege 33: 183–185 (1978).PubMedGoogle Scholar
  75. Gibbon, J.H. and Camishion, R.C: Problems in hemostasis with extracorporeal apparatus. Annals of the New York Academy of Science 115: 195–198 (1964).Google Scholar
  76. Graeff, H.; Hafter, R. and von Hugo, R.: Akute Blutgerinnungsstörungen in der Geburtshilfe. Medizinische Welt 29: 212–216 (1978a).PubMedGoogle Scholar
  77. Graeff, H.; Holzmann, K.; Gokel, J.M.; von Hugo, R. and Hafter, R.: Pathomechanismen und Klinik der Fruchtwasserembolie. Geburtshilfe und Frauenheilkunde 38: 887–894 (1978b).PubMedGoogle Scholar
  78. Guidetti, B. and Spallone, A.: The role of antifibrinolytic therapy in the preooperative management of recently ruptured intracranial aneurysms. Surgical Neurology 15: 239–248 (1981).PubMedGoogle Scholar
  79. Guillebaud, J.; Bonnar, J.; Morehead, J. and Matthews, A.: Menstrual blood-loss with intrauterine devices. Lancet 1: 387–390 (1976).PubMedGoogle Scholar
  80. Haas, S.; Birk, M.; Wendt, P. and Blümel, G.: Pharmakologische Beeinflussung der thrombozytären Aggregatbildung und Freisetzungsreaktion in lagerndem Vollblut; in Blümel und Haas (Eds) Mikrozirkulation und Prostaglandinstoffwechsei, pp. 119–128 (F.K. Schattauer Verlag, Stuttgart/New York 1981).Google Scholar
  81. Haas, S.; Ketterl, R.; Landauer, B.; Lechner, F. and Blümel, G.: Platelet function and proteinase inhibition; in McConn (Ed.) The Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury, pp. 219–228 (Raven Press, New York 1982).Google Scholar
  82. Haas-Denk, S.; Kraunzner, W. and von Sommoggy, S.: Beeinflussung der Thrombozytenfunktion und der Gerinnung von Konservenblut durch Azetylsalizylsäure und Aprotinin. Medizinische Welt 28: 912–914 (1977).PubMedGoogle Scholar
  83. Haberland, G.L.: Use of kallikrein and Trasylol in experimental animals; in Pisano and Austen (Eds) Chemistry and Biology of the Kallikrein-Kinin System in Health and Disease, pp. 557–571 (Department of Health, Education and Welfare, Washington 1977).Google Scholar
  84. Haberland, G.L.: The role of kininogenases, kinin formation and kininogenase inhibition in post traumatic shock and related conditions. Klinische Wochenschrift 56: 325–331 (1978).PubMedGoogle Scholar
  85. Haberland, G.; Koslowski, L. and Matis, P.: Trasylol in der Schocktherapie–Wirkung und Interpretation. Medizinische Welt 23: 1049–1056 (1972).PubMedGoogle Scholar
  86. Haberland, G. and McConn, R.: A rationale for the therapeutic action of aprotinin. Federation Proceedings 38: 2760–2767 (1979).PubMedGoogle Scholar
  87. Haberland, G.L. and Matis, P.: Trasylol, ein Proteinaseninhibitor bei chirurgischen und internen Indikationen. Medizinische Welt 18: 1367–1376 (1967).Google Scholar
  88. Habermann, E.; Arndts, D.; Just, M.; Räker, K.O. and Török, P.: Das Verhalten des Trasylol im Organismus als Modell Für die Pharmakokinetik basischer Polypeptide. Medizinische Welt 24: 1163–1167 (1973).PubMedGoogle Scholar
  89. Hack, G.; Kirchhoff, P.G.; Popov-Cenić, S.; Kulzer, R.; Schlemminger, B. and Piepho, A.: Aprotinin bei Operationen am offenen Herzen. Medizinische Welt 34: 726–731 (1983).PubMedGoogle Scholar
  90. Hallberg, L.; Högdahl, A.M.; Nilsson, L. and Rybo, G.: Menstrual blood loss — a population study. Acta Obstetricia et Gynccologica Scandinavica 45: 320–351 (1966).Google Scholar
  91. Harke, H.: Beeinflussung der Mikroaggregation in lagernden Blutkonserven. Anaesthesist 25: 374–379 (1976).PubMedGoogle Scholar
  92. Harke, H.: Massivtransfusionen Hämostase und Schocklunge, pp. 95–121 (Springer-Verlag, Berlin/Heidelberg/New York 1982).Google Scholar
  93. Harke, H. and Gennrich, M.: Aprotinin-ACD-Blut: Experimentelle Untersuchungen über den Einfluss von Aprotinin auf die plasmatische und thrombozytäre Gerinnung. Anaesthesist 29: 266–276 (1980).PubMedGoogle Scholar
  94. Haverich, A.; Walterbusch, G. and Borst, H.-G: Abdichtung poröser Gefassprothesen unter Teil-Heparinisierung und extrakorporaler Zirkulation. Angio 5: 215–220 (1983).Google Scholar
  95. Hedlund, P.O.: Antifibrinolytic therapy with Cyclokapron in connection with prostatectomy. Scandinavian Journal of Urology and Nephrology 3: 177–182 (1969).PubMedGoogle Scholar
  96. Heine, H.; Trenkel, K.; Arbogast, R. and Eisenbach, J.: Funktionelle Morphologie von Endstrombahn und Transitstrecke: Probleme beim Schock. Medizinische Welt 31: 558–565 (1980).PubMedGoogle Scholar
  97. Hcmpelmann, G.; Trentz, O.A.; Trentz, O.; Müller, H.; Oestern, H.-J. and Sturm, J.: Behandlung des polytraumatischen Schocks. Unfallchirurgie 7: 116–121 (1981).Google Scholar
  98. Hoffman, E.P. and Koo, A.H.: Cerebral thrombosis associated with Amicar. Radiology 131: 687–689 (1979).PubMedGoogle Scholar
  99. Hollanders, D.; Thomson, J.M. and Schofield, P.F.: Tranexamic acid therapy in ulcerative colitis. Postgraduate Medical Journal 58: 87–91 (1983).Google Scholar
  100. Horbach, L. and Just, H.: Trasylol in myocardial infarction. Intensivmedicin 16: 338–360 (1979).Google Scholar
  101. Hoylaerts, M.; Lijnen, H.R. and Collen, D.: Studies on the mechanism of antifibrinolytic action of tranexamic acid. Biochimica et Biophysica Acta 673: 75–85 (1981).PubMedGoogle Scholar
  102. Imrie, C.W.; Benjamin, S.; Ferguson, J.C; McKay, A.J.; Mackenzie, I.; O’Neill, J. and Blumgart, L.H.: A single centre double blind trial of Trasylol therapy in primary acute pancreatitis. British Journal of Surgery 65: 337–341 (1978).PubMedGoogle Scholar
  103. Jerndal, T. and Frisén, M.: Tranexamic acid (AMCA) and late hyphaema. A double-blind study in cataract surgery. Acta Ophthalmologica 54: 417–429 (1976).PubMedGoogle Scholar
  104. Jochum, M.; Jonáková, V.; Dittmer, H. and Fritz, H.: An enzymatic assay convenient for the control of aprotinin levels during proteinase inhibitor therapy. Fresenius’ Zeitschrift für Analytische Chemie 317: 719–720 (1984).Google Scholar
  105. Johnston, S.J.; Jones, P.F.; Kyle, J. and Needham, Ch. D.: Epidemiology and course of gastrointestinal haemorrhage in Northeast Scotland. British Medical Journal 3: 655–660 (1973).PubMedGoogle Scholar
  106. Kaller, H.: Enterale Resorption, Verteilung and Elimination von 4-aminomethylcyclohexancarbonsäure (AMCHA) und ∈-aminocapronsäure (EACS) beim Menschen. Naunyn-Schmiedebergs Archiv für Pharmakologie und Experimentelle Pathologie 256: 160–168 (1967).Google Scholar
  107. Kaller, H.; Hoffmeister, F. and Kroneberg, G.: Die Wirkung von Trasylol auf verschiedene Ödemformen der Rattenpfote. Archives Internationales de Pharmacodynamie et de Thérapie 161: 398–409 (1966).PubMedGoogle Scholar
  108. Kaller, H.; Patzschke, K.; Wegner, L.A. and Horster, F.A.: Pharmacokinetic observations following intravenous administration of radioactive labelled aprotinin in volunteers. European Journal of Drug Metabolism and Pharmacokinetics 3: 79–85 (1978).Google Scholar
  109. Kamp Mortensen, K. and Sjölie, A.K.: Secondary haemorrhage following traumatic hyphaema. A comparative study of conservative and tranexamic treatment. Acta Ophthalmologica 56: 763–768 (1978).Google Scholar
  110. Kaplan, A.P.; Silverberg, M.; Dunn, J.T. and Ghebrehiwet, B.: Interaction of the clotting, kininforming, complement and fibrinolytic pathways in inflammation. Annals of the New York Academy of Sciences 409: 25–37 (1982).Google Scholar
  111. Kasonde, J.M. and Bonnar, J.: Plasminogen activators in the endometrium of women using intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology 83: 315–319 (1976).PubMedGoogle Scholar
  112. Kaste, M. and Ramsay, M.: Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke 10: 519–522 (1979).PubMedGoogle Scholar
  113. Kaufmann, J. and Siefker, K.: Medikamentöse Genkung postoperatiever Blutungen nach Prostatiktomien. Urologie 8: 57–59 (1969).Google Scholar
  114. Ketterl, R.; Haas, S.; Heiss, A.; Fritsche, H.-M.; Lechner, F.; Kienzle, H. and Blümel, G.: Zur Wirkung des natürlichen Proteinaseninhibitors Aprotinin auf die Plättchenfunktion beim alloarthroplastischen Hüftgelenkersatz. Medizinische Welt 33: 480–486 (1982).PubMedGoogle Scholar
  115. Ketterl, R.; Haas, S.; Lechner, F.; Kienzle, H. and Blümel, G.: Wirkung von Aprotinin auf die Thrombozytenfunktion während Hüft-Totalendoprothesenoperationen. Medizinische Welt 31: 1239–1243 (1980).PubMedGoogle Scholar
  116. Kinn, A.C.: Konisation vid cancer in situ. Läkartidningen 67: 2529–2532 (1970).PubMedGoogle Scholar
  117. Kletter, G.; Matras, H. and Dinges, H.P.: Zur partiellen Klebung von Mikrogefässanastomosen im intrakraniellen Bereich. Wiener Klinische Wochenschrift 90: 415–419 (1978).PubMedGoogle Scholar
  118. Kondo, M.; Fukumoto, K.; Yoshikawa, T.; Takemura, S.; Hotta T.; Sugihara, M.; Furukawa, Y.; Matsuura, S. and Natsu, K.: Tissue fibrinolysis in the digestive mucosa. III. Treatment of ulcerative colitis by the direct administration of an antifibrinolytic agent as an enema. Nippon Shokakibyo Gakkai Zasshi 3: 653–657 (1981).Google Scholar
  119. Kondo, M.; Ibezaki, M.; Kato, H. and Masuda, M.: Antifibrinolytic therapy of giant hypertrophie gastritis (Menetrier’s disease). Scandinavian Journal of Gastroenterology 13: 851–856 (1978).PubMedGoogle Scholar
  120. Köstering, H.; Kirchhoff, P.G.; Völker, P.; Warmann, E. and Koncz, J.: Untersuchungen der Blutgerinnungsveränderungen während und nach Operationen mit Hilfe der Herz-Lungen-Maschine. Thoraxchirurgie 21: 534–543 (1973).Google Scholar
  121. Rösters, S. and Wand, H.: Über die Beeinflussung des Blutverlustes nach Prostataoperationen durch prä-operative Applikation von Antifibrinolytika. Urologe A 12: 295–296 (1973).Google Scholar
  122. Kolbow, H.; Bartheis, M.; Oestern, H.-J.; Sturm, J.; Wannske, M. and Schaps, D.: Frühveränderungen des Gerinnungssystems beim Polytrauma und seine Beeinflussung durch Heparin und Trasylol. Langenbecks Archiv für Chirurgie (Suppl. Chir. Forum): 119–123 (1977).Google Scholar
  123. Koos, W.; Kraus, H.; Blümel, G. and Boeck, F.: Le mode d’action des inhibiteurs de protéinases (Trasylol) dans les hémorragies intra-cräniennes. Neurochirurgie 16: 548–550 (1970).PubMedGoogle Scholar
  124. Kramer, H.-J.; Moch, T.; Von Sicherer, L. and Düsing, R.: Effects of aprotinin on renal function and urinary prostaglandin excretion in conscious rats after acute salt loading. Clinical Science 56: 547–553 (1979).PubMedGoogle Scholar
  125. Kraut, E.; Frey, E.K. and Werte, E.: Über die Inaktivierung des Kallikreins. Hoppe-Seyler’s Zeitschrift für Physiologische Chemie 192: 1–21 (1930).Google Scholar
  126. Kullander, S. and Nilsson, I.M.: Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstetricia et Gynecologica Scandinavica 49: 241–242 (1970).PubMedGoogle Scholar
  127. Kunitz, M. and Northrop, J.H.: Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and an inhibitor trypsin compound. Journal of General Physiology 19: 991–1007 (1936).PubMedGoogle Scholar
  128. Kwaan, H.C. and Astrup, T.: Tissue repair in presence of locally applied inhibitors of fibrinolysis. Experimental and Molecular Pathology 11: 82–88 (1969).PubMedGoogle Scholar
  129. Kwaan, H.C; Cocco, A.; Mendeloff, A.I. and Astrup, T.: Fibrinolytic activity in the normal and inflamed rectal mucosa. Scandinavian Journal of Gastroenterology 4: 441–445 (1969).PubMedGoogle Scholar
  130. Landin, L.E. and Weiner, E.: Late bleeding after conization. The effect of tranexamic acid (Cyclokapron). Opuscula Medica 20: 280–284 (1975).Google Scholar
  131. Larsson, B.; Liedholm, P. and Astedt, B.: Increased fibrinolytic activity in the endometrium of patients using copped IUD (Gravigard). International Journal of Fertility 20: 77–80 (1975).PubMedGoogle Scholar
  132. Lasson, A.; Dittmann, B. and Ohlsson, K.: Influence of plasma proteinase inhibitors and aprotinin on trypsin-induced bradykinin release in vitro in man. Hoppe-Seyler’s Zeitschrift für Physiologische Chemie 364: 1315–1322 (1983).PubMedGoogle Scholar
  133. Lasson, A. and Ohlsson, K.: An in vitro study of the influence of plasma protease inhibitors and aprotinin on trypsin-induced C3 cleavage in human serum. Biochimica et Biophysica Acta 709: 227–233 (1982).PubMedGoogle Scholar
  134. Laurberg, G.: Tranexamic acid (Cyclokapron) in chronic urticaria: A double-blind study. Acta Dermato-Venereologica 57: 369–370 (1977).PubMedGoogle Scholar
  135. Lazdunski, M.; Vincent, J.P.; Schweitz, H.; Peron-Renner, M. and Pudles, J.: Mechanism of association with trypsin (or chymotrypsin) with pancreatic trypsin inhibitor (Kunitz and Rajal) kinetics and thermodynamics of the inter-reaction; in Fritz et al. (Eds) Proteinase Inhibitors, pp. 420–431 (Springer Verlag, Berlin/Heidelberg/New York 1974).Google Scholar
  136. Lefer, A.M. and Spath, J.A.: Protective effect of protease inhibition in myocardial ischemia; in Cantin et al. (Eds) New Aspects of Trasylol Therapy Vol. 8, pp. 311–328 (F.K. Schattauer Verlag, Stuttgart/New York 1975).Google Scholar
  137. Leheta, F.; Lenz, C.; Weichenmeier, I.; Haas, S. and Bluemel, G.: Die Beeinflussung der Fibrinolyse am traumatisierten Rattenhirn durch lokale Applikation von Aprotinin, Wasserstoffperoxid und physiologischer NaCl-Lösung Medizinische Welt 33: 1802–1804 (1982).Google Scholar
  138. Lewis. J.H. and Doyle, A.P.: Effects of epsilon-aminocaproic acid on coagulation and fibrinolytic mechanisms. Journal of the American Medical Association 188: 56–63 (1964).PubMedGoogle Scholar
  139. Lewis, M.L.: Trasylol for pancreatitis (Correspondence). British Medical Journal 3: 741–742 (1974).PubMedGoogle Scholar
  140. Liedholm, P.; Astedt, B. and Kullander, S.: Passage of tranexamic acid (AMCA) to semen in man and its effect on the fibrinolytic activity and in migration of spermatozoa. Fertility and Sterility 24: 517–520 (1973).PubMedGoogle Scholar
  141. Lohmann, K.; Markwardt, F. and Landmann, H.: Über neue Hemmstoffe der Fibrinolyse. Naturwissenschaften 50: 502 (1963).Google Scholar
  142. Lundsgaard-Hansen, P.: Is there a rationale for using a proteinase inhibitor as a standard additive to stored blood? Vox Sanguinis 45: 1–5 (1983).PubMedGoogle Scholar
  143. Mammen, E.F.: Natural proteinase inhibitors in extracorporeal circulation. Annals of the New York Academy of Sciences 146: 754–761 (1968).PubMedGoogle Scholar
  144. Marcello, B. and Porati, N.: Trasylol e blocco neuromuscolare. Minerva Anestesiologica (Torino) 33: 814–819 (1967).Google Scholar
  145. Markwardt, F.: Synthetic inhibitors of fibrinolysis; in Markwardt (Ed.): Fibrinolytics and Antifibrinolytics, pp. 511–577 (Springer Verlag, Berlin/Heidelberg/New York 1978).Google Scholar
  146. Markwardt, F. and Klöcking, H.P.: Über das Stoffwechselschicksal der p-Aminomethylbenzosäure (PAMBA) beim Menshcen. Acta Biologica et Medica Germanica 14: 519–526 (1965).PubMedGoogle Scholar
  147. Markwardt, F.; Nowak, G.; Meerbach, W. and Rüdiger, K.D.: The influence of drugs on disseminated intravascular coagulation (DIC). I. Effects of antifibrinolytics and fibrinolytics on thrombin-induced DIC in rats. Thrombosis Research 9: 143–152 (1976).PubMedGoogle Scholar
  148. Mary, A.; Cros, G.; Modat, G. and Lalaurie, M.: Agrégation in vitro des plaquettes de rat par doses cumulées d’ADP: Influence de trois antiagrégants et d’un inhibiteur protéasique, l’aprotinine. Comptes Rendus des Seances de la Societé de Biologie 177: 320–331 (1983).Google Scholar
  149. Maurice-Williams, R.C.: Prolonged antifibrinolysis: An effective non-surgical treatment for ruptured intracranial aneurysms? British Medical Journal 1: 945–947 (1978).PubMedGoogle Scholar
  150. McMichan, J.C.; Rosengarten, D.S. and Philipp, E.: Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: A clinial study. Circulatory Shock 9: 107–116 (1982).PubMedGoogle Scholar
  151. McNicol, G.P.; Fletcher, A.P.; Alkjaersig, N. and Sherry, S.: The absorption, distribution and excretion of epsilon-amino-caproic acid following oral or intravenous administration to man. Journal of Laboratory and Clinical Medicine 59: 15–24 (1962).Google Scholar
  152. McNicol, G.P.; Prentice, C.R.M. and Douglas, A.S.: Trasylol and failure of hemostasis; in Donatelli et al. (Eds) Proteases and Antiproteases in Cardioangiology, pp. 89–97 (F.K. Schattauer Verlag, Stuttgart/New York 1970).Google Scholar
  153. Medical Research Council Multicentre Trial: Morbidity of acute pancreatitis; the effect of aprotinin and glucagon. Gut 21: 334–339 (1980).Google Scholar
  154. Melander, B.; Gleneecki, G.; Granstrand, B. and Hanshoff, G.: Biochemistry and toxicology of Amikapron: The antifibrinolytic active isomer of AMCHA. Acta Pharmacologica et Toxicologica 22: 340–352 (1965).PubMedGoogle Scholar
  155. Miller, R.A.; May, M.W.; Hendry, W.F.; Whitfield, H.W. and Wickham, J.E.A.: The prevention of secondary haemorrhage after prostatectomy: The value of antifibrinolytic therapy. British Journal of Urology 52: 26–28 (1980).PubMedGoogle Scholar
  156. Missotten. L.; de Clippeleer, L.; Van Tornout, I. and Beenders, P.: The value of tranexamic acid (Cyclokapron) in the prevention of secondary bleeding, a complication of traumatic hyphaema. Bulletin de la Société Belge d’Ophtalmolgie 179: 47–52 (1977).Google Scholar
  157. Monta, H.; Tachizowa, H. and Akimoto, T.: Evaluation of the safety of tranexamic acid. Teratogenic effects in mice and rats. Oyo Yakuri 5: 415–420 (1971).Google Scholar
  158. Mowat, N.A.G.; Douglas, A.S.; Brunt, P.W.; McIntosch, J.A.R.; King, P.C. and Boddy, K.: Epsilon aminocaproic acid therapy in ulcerative colitis. American Journal of Digestive Diseases 18: 959–965 (1973).PubMedGoogle Scholar
  159. Murday, H.; Orellano, L.; Fenyes, J.; Popov-Cenić, S. and Kirchhoff, P.G.: Can excessive perioperative bleeding in cardiac surgery be reduced by means of an early treatment with either aprotinin or a new C1-protease-inhibitor? The Thoracic and Cardiovascular Surgeon (Special Issue I) 32: 88 (1984).Google Scholar
  160. Naeye, L.: Thrombotic state after hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid. Blood 19: 694–701 (1962).PubMedGoogle Scholar
  161. Nagaoka, H. and Katori, M.: Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in openheart surgery. Circulation 52: 325–332 (1975).PubMedGoogle Scholar
  162. Naito, S.-I,; Hirano, M.; Yoshihara, H. and Ohta, M.: Pharmacokinetics on blood concentration of aprotinin (Trasylol) in humans. Basic Pharmacology and Therapeutics 8: 3613–3627 (1980).Google Scholar
  163. Nakahara, M.: Inhibitory effect of aprotinin and gabexate mesilate on human plasma kallikrein. Arzneimittel-Forschung 33: 969–971 (1983).PubMedGoogle Scholar
  164. Nibblelink, D.W.: Cooperative aneurysm study: Antihypertensive and antifibrinolytic therapy following subarachnoid haemorrhage from ruptured intracranial aneurysm; in Whisnant et al. (Eds) Cerebral Vascular Disease pp. 155–173 (Grune and Stratum, New York 1975).Google Scholar
  165. Nilsson, L. and Rybo, G.: Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). A double blind investigation. Acta Obstetricia et Gynecologica Scandinavica 46: 572–580 (1967).Google Scholar
  166. Nilsson, L. and Rybo, G.: Treatment of menorrhagia. American Journal of Obstetrics and Gynecology 110: 713–720 (1971).PubMedGoogle Scholar
  167. Oeney, T.; Schander, K.; Müller, N.; Fromm, G. and Lang, N.: Fruchtwasserembolie mit Gerinnungsstörung ein kasuistischer Beitrag. Geburtshilfe und Frauenheilkunde 42: 25–28 (1982).Google Scholar
  168. Okamoto, S. and Hijikata, A.: Rational approach to proteinase inhibitors. Drug Design 6: 143–169 (1975).Google Scholar
  169. Okamoto, S.; Oshiba, S.; Mihara, H. and Okamoto, U.: Synthetic inhibitors of fibrinolysis: In vitro and in vivo mode of action. Annals of the New York Academy of Sciences 146: 414–429 (1968).PubMedGoogle Scholar
  170. Okamoto, S.; Sato, S.; Takada, Y. and Okamoto, U.: An active stereo isomer (trans form) of AMCHA and its fibrinolytic (antiplasminic) action in vitro and in vivo. Keio Journal of Medicine 13: 177–185 (1964).PubMedGoogle Scholar
  171. Olsen, T.; Ehlers, N. and Bramsen, T.: Influence of tranexamic acid and acetylsalicylic acid on the thickness of the normal cornea. Acta Ophthalmologica 58: 767–782 (1980).PubMedGoogle Scholar
  172. Overlack, A.; Stumpe, K.O.; Kühnert, M.; Koloch, R.; Ressel, C.; Heck, I. and Krück, F.: Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition. Klinische Wochenschrift 59: 69–74 (1981).PubMedGoogle Scholar
  173. Overlack, A.; Stumpe, K.O.; Müller, H.-M.; Kolloch, R. and Higuchi, M.: Interactions of diuretics with the renal kallikreinkinin and prostaglandin systems. Klinische Wochenschrift 60: 1223–1228 (1982).PubMedGoogle Scholar
  174. Pandolifi, M.: Intraocular haemorrhages: A haemostatic therapeutic approach. Survery of Ophthalmology 22: 322–334 (1978).Google Scholar
  175. Pauschinger, P.; Matis, P. and Rieckert, H.: Circulatory changes in the area of the lower extremities secondary to inactivity and the influence exerted on them by Trasylol; in Haberland and Matis (Eds) New Aspects of Trasylol Therapy Vol. 3, pp. 83–90 (F.K. Schattauer Verlag, Stuttgart, New York 1970).Google Scholar
  176. Petruson, B.: A double-blind study to evaluate the effect of epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (cyclokapron). Acta Oto-Laryngologica Suppl. 317: 57–61 (1974).Google Scholar
  177. Pfeifer, G.W.: Proteinasenblockade bei abgestorbener Schwangerschaft, “dead fetus syndrome”. Deutsche Medizinische Wochenschrift 93: 479–485 (1968).PubMedGoogle Scholar
  178. Philipp, E.: Calculations and hypothetical considerations on the inhibition of plasmin and plasma kallikrein by Trasylol; in Davidson, Desnoyers et al. (Eds) Progress in Chemical Fibrinolysis and Thrombolysis, pp. 291–295 (Raven Press, New York 1978).Google Scholar
  179. Pilbrant, A.; Shannong, M. and Vessman, J.: Pharmacokinetics and bioavailability of tranexamic acid. European Journal of Clinical Pharmacology 20: 65–72 (1981).PubMedGoogle Scholar
  180. Popov-Cenić, S.; Urban, A.E. and Noë, G.: Studies on the cause of bleeding during and after surgery with a heart-lung machine in children with cyanotic and acyanotic congential cardiac defects and their prophylactic treatment; in McConn (Ed) Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury, pp. 229–242 (Raven Press, New York 1982).Google Scholar
  181. Prentice, C.R.M.; McNicol, G.P. and Douglas, A.S.: Studies on the anticoagulant action of aprotinin (Trasylol). Thrombosis et Diathesis Haemorrhagica 24: 265–272 (1970).PubMedGoogle Scholar
  182. Rainsford, S.G.; Jouhar, A.J. and Hall, A.: Tranexamic acid in the control of spontaneous bleeding in severe haemophilia. Thrombosis et Diathesis Haemorrhagica 30: 272–279 (1973).PubMedGoogle Scholar
  183. Ramirez-Lassepas, M: Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial bleeding. Neurology 31: 316–322 (1981).PubMedGoogle Scholar
  184. Ramström, G. and Blombäck, M.: Tooth extraction in hemophiliacs. International Journal of Oral Surgery 4: 1–17 (1975).PubMedGoogle Scholar
  185. Rao, A.K.; Schmaier, A.H. and Colman, R.W.: Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets; in loachim (Ed.) Pathobiology Annual 1982, pp. 35–64 (Raven Press, New York 1982).Google Scholar
  186. Reuter, H.D.; Czybulka, I. and Zanger, I.: Der Einfluss von Trasylol auf Plättchenaggregation, Plättchenretention und Plättchenfaktor-3-Verfügbarkeit; in Ludwig und Genz (Eds) Blutgerinnung und Gefässwand, pp. 269–278 (F.K. Schattauer Verlag, Stuttgart/New York 1981).Google Scholar
  187. Reuter, H.D.; Selbherr, J.; Hannekum, A.; Dalichau, H. and Busse, J.: The effect of aprotinin on platelet counts and functions in the course of open heart surgery. The Thoracic and Cardiovascular Surgeon (Special Issue I) 32: 87 (1984).Google Scholar
  188. Rö, J.S.; Knutrud, O. and Stormorken, H.: Antifibrinolytic treatment with tranexamic acid (AMCHA) in Pediatric urinary tract surgery. Journal of Pediatric Surgery 5: 315–320 (1970).PubMedGoogle Scholar
  189. Rybo, G.: Plasminogen activators in the endometrium II. Clinical aspects. Acta Obstetricia et Gynecologica Scandinavica 45: 429–450 (1966).PubMedGoogle Scholar
  190. Rybo, G. and Westerberg, H.: The effect of tranexamic acid (AMCA) on postoperative bleeding after conization. Acta Obstetricia et Gynecologica Scandinavica 51: 347–350 (1972).PubMedGoogle Scholar
  191. Rydin, E. and Lundberg, P.O.: Tranexamic acid and intracranial thrombosis. Lancet 2: 49 (1976).PubMedGoogle Scholar
  192. Schmutzler, R. and Fürstenberg, H.: Fibrinolyse und Blutverlust nach Prostata-Operationen und deren Beeinflussbarkeit durch Antifibrinolytika. Deutsche Medizinische Wochenschrift 91: 297–303 (1966).PubMedGoogle Scholar
  193. Schneider, B.: Results of a field study on the therapeutic value of aprotinin in traumatic shock. Arzneimittel-Forschung 26: 1606–1610 (1976).PubMedGoogle Scholar
  194. Sharp, A.A.: Pathological fibrinolysis. British Medical Bulletin 20: 240–246 (1964).PubMedGoogle Scholar
  195. Sheffer, A.L.; Austin, K.F. and Rosen, F.S.: Tranexamic acid therapy in hereditary angioneurotoic edema. New England Journal of Medicine 287: 452–454 (1972).PubMedGoogle Scholar
  196. Sher, G.: Trasylol in the management of abruptio placentae with consumption coagulopathy and uterine inertia. Journal of Reproductive Medicine 25: 113–118 (1980).PubMedGoogle Scholar
  197. Shimada, H.; Nagai, E.; Monta, H. and Akimoto, T.: Mutagenicity studies of tranexamic acid. Oyo Yakuri 18: 165–172 (1979).Google Scholar
  198. Sjoerdsma, A. and Nilsson, I.M.: Alipathic amino compounds as inhibitors of plasminogen activation. Proceedings of the Society for Experimental Biology and Medicine 103: 533–538 (1960).Google Scholar
  199. Sonntag, V.K.H. and Stein, B.M.: Arteriopathic complications during treatment of subarachnoid haemorrhage with epsilonaminocaproic acid. Journal of Neurosurgery 40: 480–485 (1974).PubMedGoogle Scholar
  200. Stürzebecher, J. and Markwardt, F.: Synthetische Inhibitoren des Thrombosis und andere Gerinnungsenzyme. Struktur and Wirkung. Beitrage zur Wirkstofforschung 16: 1–92 (1982).Google Scholar
  201. Sunamori, M.; Amano, J.; Kameda, T.; Okamura, T.; Ozeki, M. and Suzuki, A.: Additive protection of aprotinin, protease inhibitor to cold cardioplegia from ischemie myocardium. Japanese Circulation Journal 44: 771–775 (1980).PubMedGoogle Scholar
  202. Sunamori, M.; Amano, J.; Okamura, T. and Suzuki, A.: Cardioprotective effect of aprotinin in open heart surgery (Abstract 17). Presented at the 3rd International Symposium on Proteases — Antiproteases in Clinical Practice, Brussels, October 1982.Google Scholar
  203. Svanberg, L.: Åstedt, B. and Nilsson, I.M.: Abruptio placentae. Treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstetricia et Gynecologica Scandinavica 59: 127–130 (1980).PubMedGoogle Scholar
  204. Tauber, P.F.: Uterine Blutungen bei intrauteriner Kontrazeption. Medizinische Welt 30: 1547–1553 (1979).PubMedGoogle Scholar
  205. Tauber, P.F.; Herting, W.; Zanefeld, L.J.D.; Propping, D. and Ludwig, H.: Intrauterine contraception and its side effects: Effects of local proteinase inhibition; in Ludwig and Tauber (Eds) Human Fertilization, pp. 261–270 (Georg Thieme, Stuttgart 1978).Google Scholar
  206. Tauber, P.F.; Wolf, A.S.; Herting, W. and Zaneveld, L.J.D.: Hemorrhage induced by intrauterine devices: Control by local proteinase inhibition. Fertility and Sterility 28: 1375–1377 (1977).PubMedGoogle Scholar
  207. Tavenner, R.W.H.: Epsilon-aminocaproic acid in the treatment of hemophilia and Christmas disease with special reference to the extraction of teeth. British Dental Journal 124: 19–22 (1968).PubMedGoogle Scholar
  208. Teasdale, G.; Lindsay, K.W.; Cheah, K.C.; Murray, G.; van Gijn, J.; Vermeulen, R.; Hijdra, A.; Muizelaar, J.P. and van Crevel, H.: Antifibrinolytic treatment in subarachnoid haemorrhage, a definitive study; in Brihaye et al. (Eds) Abstracts of the 7th European Congress of Neurosurgery, 28 Aug.–3 Sept, 1983. Theil, P.L.: Ophthalmological examination of patients in long-term treatment with tranexamic acid. Acta Ophthalmologica 59: 237–241 (1981).Google Scholar
  209. Thorsen, S.: Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis and the effect of natural proteinase inhibition and ω-aminocarbocylic acids, p 20, (Laegeforeningens Forlag, Copenhagen, 1972).Google Scholar
  210. Thorsen, S.: Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega amino-carboxylic acids. Biochimica et Biophysica Acta 393: 55–65 (1975).PubMedGoogle Scholar
  211. Tice, D.A.; Worth, M.H.; Ciauss, R.H. and Reed, G.H.. The inhibition by Trasylol of fibrinolytic activity associated with cardiovascular operations. Surgery, Gynecology and Obstetrics 119: 71–74 (1964).PubMedGoogle Scholar
  212. Tovi, D. and Thulin, C.A.: The ability of tranexamic acid to cross the blood-brain barrier and diffuse in patients with ruptured intracranial aneurysms. Acta Neurologica Scandinavica 48: 257 (1972).Google Scholar
  213. Trapnell, J.E.; Rigby, C.C.; Talbot, C.H. and Duncan, E.H.L.: A controlled trial of Trasylol in the treatment of acute pancreatitis. British Journal of Surgery 61: 177–182 (1974).PubMedGoogle Scholar
  214. Traverso L.W. and Gomez, R.R.: Shock prevention studies. Hemodynamic measurements after administration of aprotinin and/or heparin during pancreatic cell autotransplantation in the dog, pig and monkey. Annals of Surgery 195: 479–485 (1982).PubMedGoogle Scholar
  215. Tschesche, H.: Biochemie natürlicher Proteinase-Inhibitoren. Angewandte Chemie 86: 21–40 (1974).Google Scholar
  216. Tzonos, T. and Giromini, D.: Aprotinin for intraoperative haemostasis. Neurosurgical Review 4: 193–194 (1981).PubMedGoogle Scholar
  217. Uusitalo, R.J.; Saari, M.S.; Aine, E. and Saari, K.M.: Tranexamic acid in the prevention of secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica 59: 539–545 (1981).PubMedGoogle Scholar
  218. Van de Werf, F.; Bergmann, S.R.; Fox, K.A.A.; De Geest, H.; Sobel, B.E. and Collen, D.: Coronary thrombolysis in dogs with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 69: 605–610 (1984a).PubMedGoogle Scholar
  219. Van de Werf, F.; Ludbrook, P.A.; Bergmann, S.R.; Tiefenbrunn, A.J.; Fox, K.A.A.; De Geest, H.; Verstraete, M.; Collen, D. and Sobel, B.E.: Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. New England Journal of Medicine 310: 609–613 (1984b).PubMedGoogle Scholar
  220. Van Rossum, J.; Wintzen, A.R.; Endtz, L.J.; Schoen, J.H.R. and Jorge, H.: Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: A double-blind controlled cllinicaJ trial. Annals of Neurology 2: 238–242 (1977).PubMedGoogle Scholar
  221. Varnek, L.; Dalsgaard, C; Hansen, A. and Klie, F.: The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema. Acta Ophthalmologica 58: 787–793 (1980).PubMedGoogle Scholar
  222. Vemulapalli, S. and Chiu, P.J.S.: Effect of aprotinin-induced kallikrcin inhibition on the cardiovascular and renal action of captopril in diuretic-treated dogs. Archives Internationales de Pharmacodynamie et de Therapie 262: 109–123 (1983).PubMedGoogle Scholar
  223. Vermeulen, M.; Lindsay, K.W.; Murray, G.D.; Cheah, F.; Hijdra, A.; Muizelaar, J.P.; Schannong, M.; Teasdale, G.M.; van Crevel, H. and van Gijn, J.: Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine 311: 432–437 (1984).PubMedGoogle Scholar
  224. Van Gijn, J.: Antifibrinolytic treatment in subarachoid hemorrhage. New England Journal of Medicine 311: 432–437 (1984).PubMedGoogle Scholar
  225. Vermylen, J.; Verhaegen-Declercq, M.L.; Verstraete, M. and Fierens, F.: A double-blind study of the effect of tranexamic acid in essential menorrhagia. Thrombosis et Diathesis Haemorrhagica 20: 583–587 (1968).PubMedGoogle Scholar
  226. Verstraete, M.; Tyberghein, J.; de Greef, Y.; Daems, L. and Van Hoof, A.: Double-blind trials with ethamsylate, batroxobin or tranexamic acid on blood loss after adenotonsillectomy. Acta Clinica Belgica 32: 136–141 (1977).PubMedGoogle Scholar
  227. Verstraete, M. and Vermylen, J.: Thrombosis (Pergamon Press, Oxford 1984).Google Scholar
  228. Vinckier, F. and Vermylen, J.: Wound healing following dental extraction in rabbits: Effects of tranexamic acid, warfarin anticoagulation, and socket packing. Journal of Dental Research 63: 646–649 (1984).PubMedGoogle Scholar
  229. Walzman, M. and Bonnar, J.: Effects of tranexamic acid in the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Archives of Toxicology 5 (Suppl.): 214–220 (1982).PubMedGoogle Scholar
  230. Wanke, M.; Schmidt, J. and Höhn, N.: Renal damage in post-pancreatitic shock and its therapeutic management. Experimental and clinical pathologico-anatomic findings; in Brendel and Haberland (Eds) New Aspects of Trasylol Therapy, Vol 5, pp. 81–88 (F.K. Schattauer Verlag, Stuttgart/New York 1972).Google Scholar
  231. Weimer, W.; Stibbe, J.; van Seyen, A.J.; Billiau, A.; De Somer, P. and Collen, D.: Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 2: 1018–1020 (1981).Google Scholar
  232. Werte, E.: Contribution to the biochemistry of Trasylol; in Haberland and Matis (Eds) New Aspects of Trasylol Therapy, Vol. 3, pp. 51–62 (F.K. Schattauer Verlag, Stuttgart/New York 1970).Google Scholar
  233. Werte, E.: Trasylol: A short survey on its history, biochemistry and activities; in Brendel and Haberland (Eds) New Aspects of Trasylol Therapy, Vol. 5, pp. 9–16 (F.K. Schattauer Verlag, Stuttgart/New York 1972).Google Scholar
  234. Westrom, L. and Bengtsson, L.P.: Effect of tranexamic acid (AMCA) in menorrhagia with intrauterine contraceptive devices. Journal of Reproductive Medicine 5: 154–161 (1970).PubMedGoogle Scholar
  235. Widlund, L.; Strömberg, S.; Hellström, H. and Usanius, B.: The disposition of tranexamic acid (AMCA) in various animal species and in man after oral dosage. (Data on file, Kabi AB, Stockholm, 1979).Google Scholar
  236. Wilkens, HJ.; Steger, R. and Back, N.: Effect of the protease inhibitor Trasylol in acute coronary occlusion in dogs; in Cantin et al. (Eds) New Aspects of Trasylol Therapy, vol. 8. pp. 381–392 (F.K. Schattauer Verlag, Stuttgart/New York 1975).Google Scholar
  237. Wiman, B.: On the reaction of plasmin or plasminstreptokinase complex with aprotinin or α2-antiplasmin. Thrombosis Research 17: 143–152 (1980).PubMedGoogle Scholar
  238. Wiman, B. and Collen, D.: On the kinetics of the reaction between antiplasmin and plasmin. European Journal of Biochemistry 84: 573–578 (1978).PubMedGoogle Scholar
  239. Wuepper, K.D.: Prekallikrein deficiency in man. Journal of Experimental Medicine 138: 1345–1355 (1973).PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1985

Authors and Affiliations

  • M. Verstraete
    • 1
  1. 1.Center for Thrombosis and Vascular Research, Department of Medical ResearchKatholieke Universiteit, Campus Gasthuisberg — KU LeuvenLeuvenBelgium

Personalised recommendations